Compare AstraZeneca plc (AZN) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Xcel Energy Inc — how do they compare? AstraZeneca plc trades at $158.68 (market cap $248.14B), while Xcel Energy Inc trades at $78.47 (market cap $48.51B). The key difference: AstraZeneca plc is far larger — about 5.1× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| AZN | XEL | |
|---|---|---|
Market Cap | $248.14B | $48.51B |
Sector | Health | Utilities |
52-Week High | $209.48 | $83.91 |
52-Week Low | $147.06 | $71.75 |
Enterprise Value | $275.41B | $86.82B |
Dividend Yield | 2.01% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
XEL trades at $78.09, up 1.59% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations in Q2 2026 with EPS of $0.93, driven by infrastructure investments. The company maintains solid fundamentals, including a 15.28% net income margin and a $0.59 quarterly dividend, while analyst consensus is bullish with a $93.80 price target.
Outlook is positive due to strong earnings growth and a $60 billion capital plan supporting future expansion, but risks include regulatory pushback and high debt levels. The stock offers stability with a 2.87% dividend yield, though technical resistance near $79 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
